BusinessBioLargo Sets New Sales Records and Continues to Break Through Commercial BarriersBy Nasdaq OMXNov 14, 2017, 2:30 PM UTC
BusinessBioLargo's Medical Subsidiary Files 510(k) with FDA for its Novel Wound Care TechnologyBy Nasdaq OMXSep 28, 2017, 1:12 PM UTC
BusinessBioLargo CEO Dennis Calvert Elaborates on the Importance of its new Engineering Division and Financing to Accelerate CommercializationBy Nasdaq OMXSep 20, 2017, 2:00 PM UTC
BusinessBioLargo Acquires World-Class Engineering Team to Form a New Engineering Services Subsidiary and Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park CapitalBy Nasdaq OMXSep 11, 2017, 1:30 PM UTC
BusinessKLOX Technologies reports on final results from its clinical study on LumiHeal™ for the treatment of chronic woundsBy Nasdaq OMXMay 3, 2017, 2:30 PM UTC
BusinessCrawford Supports Silver Oxysalts™ Speaker Panel at the Symposium for Advanced Wound CareBy Nasdaq OMXApr 13, 2017, 1:03 PM UTC
BusinessKLOX Technologies reports on its interim results from its ongoing clinical studies on LumiHeal™ for the treatment of chronic wounds and postsurgical scarringBy Nasdaq OMXSep 28, 2016, 10:00 AM UTC
